艾德生物 (300685.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

17.5x

EV/EBITDA

12.3x

Market Cap

CNY 7.18B

MomentumView details →

1D Return

−3.05%

YTD Return

−16.28%

RSI (14)

40.2

ValuationView details →

P/E (Fwd)

17.5x

EV/EBITDA

12.3x

Market Cap

CNY 7.18B

RSI (14)

40.2

MomentumView details →

1D Return

−3.05%

YTD Return

−16.28%

ProfitabilityView details →

Gross Margin

82.36%

Net Margin

30.01%

EBITDA Margin

39.76%

ROE (TTM)

17.30%

ROA (TTM)

14.85%

Asset Turnover

0.50x

GrowthView details →

Revenue YoY

+3.33%

EPS YoY

+28.07%

FCF YoY

−7.67%

Revenue CAGR 3Y

+12.46%

EPS CAGR 3Y

+10.74%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.20

EPS Surprise

−4.76%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.21

Avg Surprise (4Q)

−4.76%

Rev Surprise

−15.18%

Capital & dividendView details →

Debt/Equity

0.09x

Current Ratio

15.14x

Quick Ratio

14.81x

Div Yield

2.63%

Div Rate

CNY 0.45

Div Growth 1Y

+50.00%

Financials snapshotView financials →

Revenue (TTM)

1.19B

Net Income (TTM)

355.94M

Op. CF (TTM)

368.86M

Next earningsOct 27, 2026 →

Latest newsMore news →

Amoy Diagnostics announced that it has repurchased 9.1193 million shares for about 171 million yuan under its buyback program to cancel shares and reduce registered capital.3d ago

Amoy Diagnostics reported its first-half 2026 results: revenue of 559 million yuan, down 3.45% year-on-year; net profit attributable to shareholders of 166 million yuan, down 12.12% from 189 million yuan in the same period of 2025; non-recurring net profit of 162 million yuan, down 12.49%.11d ago

Similar companies

沧州明珠002108.SZ 莱宝高科002106.SZ 四会富仕300852.SZ 三钢闽光002110.SZ 聚灿光电300708.SZ 香山股份002870.SZ Find similar companies →

Latest newsMore news →

Amoy Diagnostics announced that it has repurchased 9.1193 million shares for about 171 million yuan under its buyback program to cancel shares and reduce registered capital.3d ago Amoy Diagnostics reported its first-half 2026 results: revenue of 559 million yuan, down 3.45% year-on-year; net profit attributable to shareholders of 166 million yuan, down 12.12% from 189 million yuan in the same period of 2025; non-recurring net profit of 162 million yuan, down 12.49%.11d ago